Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy Cloughesy

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio TrialThomas Sandmann, Richard Bourgon, Josep Garcia, et al.
Neuro-Oncology Advances|June 25, 2021
Erratum to: FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomasRadwa Sharaf, Dean C Pavlick, Garrett M Frampton, et al.
Neuro-Oncology Advances|March 29, 2021
FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomasRadwa Sharaf, Dean C Pavlick, Garrett M Frampton, et al.
Journal of Neuro-Oncology|March 7, 2019
SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activationFei Liu, Christopher D Cox, Reshmi Chowdhury, et al.
The Lancet. Oncology|September 30, 2021
Leveraging external data in the design and analysis of clinical trials in neuro-oncologyRifaquat Rahman, Steffen Ventz, Jon McDunn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2016
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O<sup>6</sup>-Methylguanine-DNA Methyltransferase Biomarker AnalysesTimothy Cloughesy, Gaetano Finocchiaro, Cristóbal Belda-Iniesta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2010
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiformeAlbert Lai, Anh Tran, Phioanh L Nghiemphu, et al.
Neuro-Oncology|July 6, 2019
The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patientsCraig Horbinski, Keith L Ligon, Priscilla Brastianos, et al.
Neuro-Oncology|December 6, 2013
Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshopJason T Huse, Max Wallace, Kenneth D Aldape, et al.
Cancers|July 12, 2025
Prognostic Features of Recurrent Midline and H3 K27M-Mutant GliomaStephen J Bagley, Yoshie Umemura, Joe S Mendez, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio TrialThomas Sandmann, Richard Bourgon, Josep Garcia, et al.
Neuro-Oncology Advances|June 25, 2021
Erratum to: FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomasRadwa Sharaf, Dean C Pavlick, Garrett M Frampton, et al.
Neuro-Oncology Advances|March 29, 2021
FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomasRadwa Sharaf, Dean C Pavlick, Garrett M Frampton, et al.
Journal of Neuro-Oncology|March 7, 2019
SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activationFei Liu, Christopher D Cox, Reshmi Chowdhury, et al.
The Lancet. Oncology|September 30, 2021
Leveraging external data in the design and analysis of clinical trials in neuro-oncologyRifaquat Rahman, Steffen Ventz, Jon McDunn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2016
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O<sup>6</sup>-Methylguanine-DNA Methyltransferase Biomarker AnalysesTimothy Cloughesy, Gaetano Finocchiaro, Cristóbal Belda-Iniesta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2010
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiformeAlbert Lai, Anh Tran, Phioanh L Nghiemphu, et al.
Neuro-Oncology|July 6, 2019
The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patientsCraig Horbinski, Keith L Ligon, Priscilla Brastianos, et al.
Neuro-Oncology|December 6, 2013
Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshopJason T Huse, Max Wallace, Kenneth D Aldape, et al.
Cancers|July 12, 2025
Prognostic Features of Recurrent Midline and H3 K27M-Mutant GliomaStephen J Bagley, Yoshie Umemura, Joe S Mendez, et al.
Pageof 10